Search

John K Leypoldt

from San Clemente, CA
Age ~69
Get Report
Also known as:
John Kenneth Leypoldt, John G Leypoldt, John K Lepold, John T
Phone and address:
416 Avenida Santa Barbara APT A, San Clemente, CA 92672
(224) 433-6616
Related to:
Michelle StewartKyle R Leypoldt, 40Shannon Leypoldt, 36Cherri C Leypoldt, 68
Connected to:
Anne Leyrat, 56Marcus J Leyrer, 52Randy L Leyrer, 70Stephanie M Leyrer, 34Jan H Leys, 66Jeffrey A Leys, 60Justin H Leys, 42Luella S Leys, 85Patrick J Leys, 77Albert W Leysath, 75

John Leypoldt Phones & Addresses

  • 416 Avenida Santa Barbara APT A, San Clemente, CA 92672 (224) 433-6616
  • 416 Avenida Santa Barbara, San Clemente, CA 92672
  • 416A Avenida Santa Barbara, San Clemente, CA 92672
  • 226 E Church St, Libertyville, IL 60048
  • Waukegan, IL
  • San Diego, CA
  • 1415 Downington Ave, Salt Lake City, UT 84105
  • Lane, IL
  • Orange, CA
  • San Marcos, CA

Work

Position: Independent consultant

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Uc San Diego 1976 to 1981 Specialities: Bioengineering

Skills

Biomedical Engineering • Clinical Research • Design Control • Biotechnology • Clinical Trials • Medical Devices

Industries

Medical Devices

Resumes

Resumes

John Leypoldt Photo 1

Independent Consultant

Location:
416 Avenida Santa Barbara, San Clemente, CA 92672
Industry:
Medical Devices
Work:

Independent Consultant
Education:
Uc San Diego 1976 - 1981
Doctorates, Doctor of Philosophy, Bioengineering
Skills:
Biomedical Engineering
Clinical Research
Design Control
Biotechnology
Clinical Trials
Medical Devices

Publications

Wikipedia

John Leypoldt

John Howard Leypoldt (March 31, 1946 - February 7, 1987) was a former American football placekicker who played eight seasons in the National Football League.

Us Patents

Therapy Prediction And Optimization For Renal Failure Blood Therapy, Especially Home Hemodialysis

US Patent:
20120029324, Feb 2, 2012
Filed:
Apr 15, 2011
Appl. No.:
13/088064
Inventors:
John Kenneth Leypoldt - Libertyville IL, US
Baris Ugur Agar - Chicago IL, US
Assignee:
BAXTER HEALTHCARE S.A. - Glattpark (Opfikon)
BAXTER INTERNATIONAL INC. - Deerfield IL
International Classification:
A61B 5/15
US Classification:
600309
Abstract:
A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

Peritoneal Dialysis Solutions Comprising Glucose Polymers

US Patent:
20120238525, Sep 20, 2012
Filed:
Mar 14, 2012
Appl. No.:
13/419701
Inventors:
John Kenneth Leypoldt - Libertyville IL, US
Clifford J. Holmes - Glenview IL, US
Sujatha Karoor - Lake Forest IL, US
Catherine M. Hoff - Lake Bluff IL, US
Leo Martis - Long Grove IL, US
Rahul Tandon - Grayslake IL, US
Assignee:
BAXTER HEALTHCARE S.A. - Glattpark (Opfikon)
BAXTER INTERNATIONAL INC. - Deerfield IL
International Classification:
A61K 31/715
A61P 13/12
A61K 31/718
US Classification:
514 58, 514 54, 514 60
Abstract:
Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.

Therapy Prediction And Optimization For Renal Failure Blood Therapy, Especially Home Hemodialysis

US Patent:
20110257891, Oct 20, 2011
Filed:
Apr 15, 2011
Appl. No.:
13/088044
Inventors:
John Kenneth Leypoldt - Libertyville IL, US
Baris Ugar Agar - Chicago IL, US
Assignee:
BAXTER HEALTHCARE S.A. - Glattpark (Opfikon)
BAXTER INTERNATIONAL INC. - Deerfield IL
International Classification:
G06F 19/00
US Classification:
702 19
Abstract:
A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
Control profile
John K Leypoldt from San Clemente, CA, age ~69 Get Report